Cannabis sativa L. is a plant lengthy utilised for its textile fibers, seed oil, and oleoresin with medicinal and psychoactive properties. It is the principal supply of phytocannabinoids, with more than 100 compounds detected so far. In current years, a lot of interest has been offered to the principal phytochemicals present in Cannabis sativa L., namely, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). Compared to THC, CBD has non-psychoactive effects, an benefit for clinical applications of anti-tumor added benefits. The overview is developed to deliver an update relating to the multi-target effects of CBD in unique forms of cancer. The principal concentrate is on the most current in vitro and in vivo research that present information relating to the anti-proliferative, pro-apoptotic, cytotoxic, anti-invasive, anti-antiangiogenic, anti-inflammatory, and immunomodulatory properties of CBD with each other with their mechanisms of action. The most current clinical proof of the anticancer effects of CBD is also outlined. In addition, the principal elements of the pharmacological and toxicological profiles are offered.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 31775230 DOI: 10.3390/ijms20235905
Kis B1,two, Ifrim FCthree, Buda Vfour, Avram S1, Pavel IZ1, Antal Dfive, Paunescu Vtwo,six, Dehelean CA7, Ardelean Ffive, Diaconeasa Zeight, Soica C9, Danciu C1.